Abstract-Pressure-induced tone (myogenic, MT) and flow (shear stress)-induced dilation (FD) are potent modulators of resistance artery tone. We tested the hypothesis that locally produced angiotensin II interacts with MT and FD. Rat mesenteric resistance arteries were perfused in situ. Arterial diameter was measured by intravital microscopy after a bifurcation on 2 distal arterial branches equivalent in size (150 m, nϭ7 per group). One was ligated distally and thus submitted to pressure only (MT, no FD). The second branch was submitted to flow and pressure (MT and FD). The difference in diameter between the 2 vessels was considered to be FD. Flow-diameter-pressure relationship was established in the absence and then in the presence of 1 of the following agents. In the nonligated segment (MTϩFD), angiotensin II type 1 (AT 1 ) receptor blockade (losartan) had no significant effect, whereas angiotensin II type 2 (AT 2 ) receptor blockade (PD123319) or saralasin (AT 1 ϩAT 2 blocker) decreased the diameter significantly, by 9Ϯ1 and 10Ϯ0.8 m, respectively. Angiotensin II in the presence of losartan increased the diameter by 18Ϯ0.6 m (inhibited by PD123319). PD123319 or saralasin had no effect after NO synthesis blockade or after endothelial disruption. In the arterial segment ligated distally (MT only), AT 1 or AT 2 receptor blockade had no significant effect. AT 2 -dependent dilation represented 20% to 39% of FD (shear stress from 22 to 37 dyn/cm 2 ), and AT 2 -receptor mRNA was found in mesenteric resistance arteries. Thus, resistance arterial tone was modulated in situ by locally produced angiotensin II, which might participate in flow-induced dilation through endothelial AT 2 receptor activation of NO release. Key Words: blood vessels Ⅲ myogenic Ⅲ arteries Ⅲ stress, mechanical Ⅲ angiotensin II Ⅲ bradykinin F low (shear stress)-induced vasodilation and pressure (tensile stress)-induced tone (myogenic tone) play a key role in the control of vascular tone. [1] [2] [3] [4] [5] [6] In resistance arteries, pressure or stretch induces myogenic tone, 6 -8 which is opposed by flow-induced dilation, in vitro as well as in vivo. 3, 5, 6, 8, 9 Whereas myogenic tone is mainly independent of endothelial factors, 6,8 shear stress has been widely shown to induce the release of endothelium-derived vasoactive agents. 1, 4, 5, 10, 11 The local tissue renin-angiotensin system 12-14 is another potent regulator of vascular tone. At physiological concentrations, angiotensin II amplifies agonist-induced contractions. [13] [14] [15] Angiotensin II also activates nitric oxide (NO) production by vascular endothelial cells through angiotensin II type 1 receptor (AT 1 ) activation 16 or through angiotensin II type 2 (AT 2 ) receptor activation. 17, 18 Although no relation between flow-induced dilation and angiotensin II is known as yet, angiotensin II production may be activated by stretch in cardiac myocytes. 19.20 Moreover, in the aorta, stretch and angiotensin II synergistically activate DNA and protein synthesis. 21 Nevertheless, the role of angiotensin II in the functional response of resistance arteries to pressure and to flow is not yet known. We hypothesized that locally produced angiotensin II might play a role in the acute response (changes in diameter) of resistance arteries to pressure (myogenic tone) and/or to flow (flow-induced dilation).
F low (shear stress)-induced vasodilation and pressure (tensile stress)-induced tone (myogenic tone) play a key role in the control of vascular tone. [1] [2] [3] [4] [5] [6] In resistance arteries, pressure or stretch induces myogenic tone, 6 -8 which is opposed by flow-induced dilation, in vitro as well as in vivo. 3, 5, 6, 8, 9 Whereas myogenic tone is mainly independent of endothelial factors, 6, 8 shear stress has been widely shown to induce the release of endothelium-derived vasoactive agents. 1, 4, 5, 10, 11 The local tissue renin-angiotensin system [12] [13] [14] is another potent regulator of vascular tone. At physiological concentrations, angiotensin II amplifies agonist-induced contractions. [13] [14] [15] Angiotensin II also activates nitric oxide (NO) production by vascular endothelial cells through angiotensin II type 1 receptor (AT 1 ) activation 16 or through angiotensin II type 2 (AT 2 ) receptor activation. 17, 18 Although no relation between flow-induced dilation and angiotensin II is known as yet, angiotensin II production may be activated by stretch in cardiac myocytes. 19.20 Moreover, in the aorta, stretch and angiotensin II synergistically activate DNA and protein synthesis. 21 Nevertheless, the role of angiotensin II in the functional response of resistance arteries to pressure and to flow is not yet known. We hypothesized that locally produced angiotensin II might play a role in the acute response (changes in diameter) of resistance arteries to pressure (myogenic tone) and/or to flow (flow-induced dilation).
In rat mesenteric resistance arteries perfused in situ, arterial diameter was measured after a bifurcation on 2 distal branches equivalent in size. One branch was perfused, and the other was ligated distally, so that it was submitted to an identical pressure but not to flow. Thus, in 1 branch (ligated), myogenic tone developed only on pressure stimulation, and in the other branch (left open), myogenic tone was opposed by flow-induced dilation. The difference in diameter between the 2 branches can be considered to be due to flow-induced dilation.
Methods

Mesenteric Artery In Situ
Twelve-week-old normotensive rats were anesthetized (sodium pentobarbital, 50 mg/kg IP), a medial laparotomy was performed, and the last loop of the small intestine was exposed and placed into a container allowing the superfusion of the preparation. The following physiological salt solution (PSS) was used (mmol/L): NaCl 130, NaHCO 3 14.9, KCl 3.7, CaCl 2 ⅐ 2H 2 O 1.6, KH 2 PO 4 1.2, MgSO 4 ⅐ 7H 2 O 1.2, glucose 11, and HEPES 10, and albumin 4%. Temperature was 37°C to 38°C, pH 7.4, PO 2 160 mm Hg, and PCO 2 37 mm Hg. Two segments of a mesenteric resistance artery, equivalent in size, were dissected free of fat and connective tissues (Figure 1 ). One branch was perfused (154Ϯ6.4 m OD, nϭ28), and the other was ligated distally, so that it was submitted to pressure but not to flow (158Ϯ6.8 m OD before ligation, nϭ28). A video camera (Pulnix, CCIR) mounted on a binocular lens allowed recording and analysis of the image of the isolated arterial segments. A polyethylene catheter (OD 0.6 mm, ID 0.28 mm) was placed in the first-generation branch of the mesenteric artery and connected to a syringe infusion pump (Harvard Apparatus) driving a 10-mL syringe (Becton Dickinson). One second-order branch was left open, and a 10-cm-long catheter, connected to a pressure transducer (Gould P10EZ), was inserted into an arterial branch located upstream of the observed segment of artery to record the mesenteric arterial pressure. Flow was measured in the perfused arterial segment with a Transonic T106 small-animal blood flowmeter (Transonic systems Inc).
Step increases in flow were performed, and each flow rate was maintained for 3 minutes. The arterial video images, arterial pressure, and flow were recorded continuously. Data were collected (Biopac data acquisition system, MP 100), recorded, and analyzed (Acqknowledge software, Biopac). Shear stress was calculated for each individual segment of artery as previously described 11 : ϭ4 ⅐ Q/ ⅐ r 3 , where is viscosity (poiseϭdyn ⅐ s Ϫ1 ⅐ cm Ϫ2 ), Q is flow (mL/s), and r is radius (cm).
Experimental Protocol
Flow-pressure-diameter relationships were established by imposing step increases in flow from 75 to 298 L/min to the mesenteric arteries.
Step increases in flow and diameter measurement were conducted under control conditions and after the addition to the superfusion PSS of 1 the following drugs for 30 minutes: losartan (10 mol/L, nϭ7) or candesartan cilexetil (10 nmol/L) was used as a specific AT 1 receptor blocker, PD 123319 (0.1, 1, or 10 mol/L, nϭ5 to 7) as a specific AT 2 receptor blocker, perindopril (10 mol/L, nϭ7) or captopril (10 mol/L, nϭ3) as angiotensinconverting enzyme inhibitors (ACEIs), [Sar 1 -Ala 8 ]angiotensin II (saralasin, 10 mol/L, nϭ7) as a nonspecific AT 1 and AT 2 receptor blocker, and HOE 140 (0.1 mol/L) as a specific bradykinin B 2 receptor blocker. Only 1 drug was used per experiment. Drugs were added to the superfusate so that both the ligated and the nonligated vessels were submitted to the same concentration of drug. Drugs added extraluminally to the bath of isolated vessels diffuse rapidly through the vascular wall. 13 The effect of PD 123319 (1 mol/L, 30 minutes) on the arterial diameter was also investigated in vessels in which the endothelium had been removed by a perfusion of 1 mL of CO 2 at a flow rate of 150 L/min 11, 14, 16 (nϭ7) or in vessels pretreated with the NO synthesis blocker N G -nitro-L-arginine methyl ester (L-NAME, 10 mol/L, 30 minutes, nϭ7).
In a separate series of experiments (nϭ7), angiotensin II (0.1 nmol/L) was perfused in mesenteric arteries pretreated with candesartan cilexetil (10 nmol/L).
At the end of each experiment, flow steps and diameter measurements were conducted in the presence of sodium nitroprusside (1 mmol/L) or EGTA (2 mmol/L) and in the absence of extracellular Ca 2ϩ to determine artery passive diameter. 10, 11, 13 Mesenteric Resistance Artery: In Vitro Preparation
Mesenteric artery segments Ϸ100 m in ID were isolated and cannulated at both ends and mounted in a video-monitored perfusion system as previously described. 13, 22, 23 Briefly, the artery segment was bathed in a 5-mL organ bath containing PSS (changed at a rate of 4 mL/min). Intraluminal pressure (100 mm Hg) was controlled by a servo perfusion system, and the arterial diameter was measured and recorded continuously with a video monitoring system (Living System Instrumentation Inc). Arteries were submitted to flow (0 to 150 L/min), and this was subsequently repeated after addition of PD 123319 (1 mol/L, nϭ7). Passive diameter was then determined. 13, [22] [23] [24] Results are given in micrometers for artery diameters and flow-induced relaxation. [22] [23] [24] In another series of experiments (nϭ6), angiotensin II (0.1 nmol/L) was perfused in mesenteric arteries after pretreatment of the vessels with the AT 1 receptor blocker candesartan cilexetil (10 nmol/L).
Reverse Transcription-Polymerase Chain Reaction Analysis of AT 2 Receptors
AT 2 receptor mRNA expression was measured by reverse transcriptionpolymerase chain reaction (RT-PCR). Total RNA was extracted from mesenteric arteries (nϭ6) with Trizol (Gibco Life Technologies). RT was performed in a reaction volume of 20 L containing 100 ng RNA, 0.4 mol/L reverse primer, 2.5 mmol/L dNTP, 6 L of BRL 5ϫ buffer, 0.6 L oligo(dT) 12 to 18 primer (0.5 g/L), 200 U Moloney murine leukemia virus reverse transcriptase, RNAse inhibitor 50 U, and dithiothreitol 10 mmol/L at 39°C for 90 minutes. The reaction was inactivated at 70°C for 10 minutes. The resulting cDNA was amplified with specific primers. For amplification of AT 2 receptor cDNA, the sense primer was 5Ј-TGAGTCCGCATTTAACTGC-3Ј (extending from base 86 to 105), and the antisense primer was 5Ј-ACCACTGAGCATATTTCTCGGG-3Ј (extending from base 600 to 622). For GAPDH, the sense primer was 5Ј-TGAAGGTCGGTGTCAACGGATTTGGC-3Ј, and the antisense primer was 5Ј-CATGTAGGCCATGAGGTCCACCAC-3Ј. The amplification profile involved denaturation at 94°C, annealing at 53°C, and extension at 72°C for 30 cycles. The PCR products were separated on a 5% polyacrylamide gel, and radioactivity was measured.
Western Blot Analysis of AT 2 Receptors
Mesenteric arteries (nϭ4) were homogenized with Vibra-Cell (Bioblock Scientific). 
Immunofluorescence Analysis of AT 2 Receptors
Segments of a mesenteric resistance artery were mounted in embedding medium (Miles, Inc), frozen in isopentane previously cooled in liquid nitrogen, and stored at Ϫ80°C. Immunostaining analysis was performed as previously described 23 on transverse cross sections 5 m thick incubated overnight at 4°C with anti-AT 2 antibodies (Eurogentec) at a dilution of 1:200 and then incubated for 30 minutes at 37°C with anti-rabbit antibodies conjugated to FITC (Amersham).
Fluorescence staining was visualized with a epifluorescence microscope (Leica). Control experiments were performed to verify the specificity of the antibodies in which the second antibody only was present or in which the first antibody (anti-COX-2-specific antibody) only was present. In these series of controls, no autofluorescence was observed.
Drugs
Losartan was provided by Dupont-Merck Pharmaceutical, PD 123319 by Parke-Davis, perindopril by Servier, HOE 140 by Hoechst AG, and cadesartan cilexetil by Astra Hässle. Other reagents were purchased from Sigma Chemical Co.
Statistical Analysis
Results are expressed as meanϮSEM. Significance of the differences between groups was determined by 2-way ANOVA for consecutive measurements (flow rates) or by 1-way ANOVA followed by a Dunnett's test when appropriate. Values of PϽ0.05 were considered to be significant.
Results
Phenylephrine-induced tone and acetylcholine-induced dilation were performed before the experimental protocol to test smooth muscle contractility and the presence of the endothelium. Phenylephrine (1 mol/L) induced a significant decrease in arterial diameter from 158Ϯ5 to 86Ϯ3 m (nϭ35). After this preconstriction with phenylephrine, acetylcholine (10 mol/L) induced a significant increase in arterial diameter, from 86Ϯ3 to 155Ϯ8 m (nϭ35). Flow-diameter and pressure-diameter relationships determined in mesenteric resistance arteries under control conditions, in situ, are shown in Figure 2 . OD and intraluminal pressure increased when flow was raised by steps. Diameter values were significantly lower in the distally ligated arterial segments (submitted to pressure but not to flow) than in the segments left open and submitted to both pressure and flow. Flow-induced dilation could be estimated as the difference between the diameter in the vessel submitted to both pressure and flow and the diameter of the vessel submitted only to pressure (Figure 2, bottom) . Flow rates measured in the arterial segment left open (with flow) ranged from 75Ϯ4.5 to 298Ϯ4.6 L/min (nϭ35). These flow rates corresponded to mesenteric arterial pressures ranging from 48Ϯ4 to 71Ϯ4 mm Hg. Passive diameter (maximal dilation), determined for each flow step (as given above) in the presence of EGTA (2 mmol/L) or sodium nitroprusside (0.1 mmol/L) and in the absence of extracellular calcium, ranged from 172Ϯ3 to 197Ϯ4 m.
The ACEI perindopril (10 mol/L, nϭ7) induced a significant increase in diameter in the mesenteric arterial branch submitted to pressure without flow and in the branch submitted to flow and pressure (Figure 3, top) . Captopril (10 mol/L, nϭ3) had an effect similar to that of perindopril (Figure 3, middle) .
Bradykinin B 2 receptor blockade (HOE 140, 0.1 mol/L, nϭ7), after pretreatment with the ACEI perindopril (10 mol/L), induced a significant decrease in diameter in the mesenteric arterial branches submitted to flow and pressure and in the mesenteric arterial branches submitted to pressure only (Figure 3, bottom) . When bradykinin B 2 receptor blockade (HOE 140, 0.1 mol/L) was used without pretreatment with perindopril, no significant change in diameter occurred in the mesenteric artery branches submitted to flow and/or pressure (0.5Ϯ1.0-to 1.8Ϯ1.6-m change in diameter, vessels with flow, nϭ5, PϭNS and 1.2Ϯ0.9-to 2.2Ϯ1.8-m change in diameter, vessels with flow, nϭ5, PϭNS).
AT 1 receptor antagonism with losartan (10 mol/L) or with candesartan cilexetil (10 nmol/L) induced no significant change The AT 2 receptor antagonist PD 123329 (10 mol/L) had no significant effect when used in a vessel pretreated with L-NAME ( Figure 6 , top) or after endothelium removal (Figure 6, bottom) . Inhibition of NO synthesis (L-NAME, 10 mol/L) induced a decrease in diameter in arteries submitted to pressure and flow ( Figure 6 ) and did not affect arteries submitted to pressure only (1.5Ϯ2.0-to 2.1Ϯ2.2-m change in diameter, nϭ7).
Perfusion of angiotensin II (0.1 mol/L) in mesenteric arteries after pretreatment of the vessel with losartan (10 mol/L) induced a significant dilation (diameter from 90Ϯ3 to 108Ϯ4 m, nϭ7, PϽ0.01). Angiotensin II-induced dilation was absent when the vessels were pretreated with losartan plus PD 123329 (10 mol/L) (diameter from 104Ϯ6 to 102Ϯ7 m, nϭ7, PϭNS) or when the endothelium was disrupted in the presence of losartan (diameter from 84Ϯ9 to 88Ϯ11 m, nϭ57, PϭNS).
In mesenteric arteries isolated in an arteriograph, in vitro, flow induced a dilation ( Figure 7 ) that was significantly less pronounced in vessels pretreated for 30 minutes with the AT 2 receptor antagonist PD 123329 (1 mol/L, Figure 7) . In isolated mesenteric arteries pretreated with candesartan (0.1 mol/L), the perfusion of angiotensin II (0.1 nmol/L) induced a significant dilation (Figure 8) .
RT-PCR of AT 2 receptors revealed the presence of AT 2 receptor mRNA (Figure 9 ), whereas Western blot analysis showed the presence of the AT 2 receptors in the wall of mesenteric resistance arteries (Figure 10 ). Immunofluorescence analysis indicated that AT 2 receptors are present in the endothelium of mesenteric resistance arteries (Figure 11 ).
Discussion
The major new finding of the present study is that endogenous angiotensin II, through the activation of endothelial AT 2 receptors, participated in flow-induced dilation in mesenteric resistance arteries in situ.
In resistance arteries, myogenic origin 6 -8 is counteracted by flow-induced dilation. 3, 5, 6, [7] [8] [9] The design of the experiments performed in the present study allowed us to measure a basal tone in the presence or in the absence of flow in 2 daughter arterial branches similar in size. In the branch distally ligated, only pressure was acting on the vessel wall, so that myogenic tone developed without opposition by flow-induced dilation. In the arterial branch submitted to both flow and pressure, myogenic tone was opposed by flowinduced dilation, so the resulting diameter was higher.
Blockade of AT 2 receptors (PD 123319) decreased the diameter of the arteries submitted to pressure and flow but did not affect the diameter of the vessels ligated distally. Blockade of AT 2 receptor blockers was concentration-dependent. In addition, because AT 1 blockade had no effect on the diameter, we used saralasin (AT 1 and AT 2 blocker) to confirm the effect of PD 123319. Moreover, the dilation depending on the AT 2 receptor stimulation by flow could be increased by the infusion of exogenous angiotensin II (in the presence of an AT 1 receptor blocker) and could be reproduced in vitro. These observations suggest that locally produced angiotensin II participates in flow-induced dilation through AT 2 receptor activation.
Previous studies support our observation that AT 2 receptor activation might be involved in flow-induced dilation. Acti- Typical RT-PCR analysis of AT 2 mRNA in rat mesenteric resistance arteries. Total RNA (100 ng) was assayed. Amplified products were electrophoresed on a 5% polyacrylamide gel. MWM indicates molecular weight marker.
vation of AT 2 receptors induces a dilation in cerebral arteries 25 and in renal afferent arterioles. 26 The AT 2 receptors mediate cGMP production and NO synthesis. 27, 28 Also in support of our observation, it has been shown that AT 2 receptor gene disruption increases blood pressure. 29, 30 Our results allow at least 2 possibilities to link shear stress and AT 2 -induced dilation: (1) flow might induce the local release of angiotensin II, which would activate AT 2 receptors. This supposes that angiotensin II locally produced acts on endothelial cells only; or (2) flow might also allow a better diffusion of endogenous angiotensin II to its receptors. In agreement with the first possibility, a recent work has shown that short-term increases in shear stress enhance ACE activity. 31 But in this case, angiotensin II produced should activate both AT 1 and AT 2 receptors, and AT 2 receptor blockade had no effect in the present study. In support of the second possibility, it has been shown that flow increases the availability of agonists by influencing their mass transport. 32, 33 Nevertheless, the precise mechanism of AT 2 -dependent flow dilation remains to be elucidated. In the present study, AT 2 -dependent vasorelaxation represented a 10-m increase in diameter. Such a change in a vascular tree might represent a considerable decrease in vascular resistance. In addition, AT 2 -dependent dilation represented 20% to 39% of the total flow-induced dilation (for shear stress values ranging from 22 to 37 dyn/cm 2 ), obtained in vessels with a spontaneous tone mainly of myogenic origin. No exogenous drug was added. The presence of AT 2 receptor and of its mRNA in the wall of mesenteric resistance arteries, evidenced by Western blot analysis, histoimmunofluorescence, and RT-PCR, is in agreement with a previous study performed in the same vessels. 34 In addition, we provided evidence by immunofluorescence that AT 2 receptors were present in the endothelium, which is in agreement with the pharmacological study described above.
Dilation induced by ACEIs in both branches (with or without flow) indicates that endogenous angiotensin II is released by the wall of small arteries in the presence or absence of flow. This result extends our previous studies, extending the vascular synthesis of angiotensin II participating in the local control of smooth muscle tone. 12-14 ACE inhibition induced similar relaxation in the vessel submitted to flow and in the vessel not exposed to flow. This dilatation was in part reversed by bradykinin B 2 receptor blockade. HOE 140 alone had no significant effect on the arterial diameter. These results are in agreement with previous studies showing that ACE inhibition induces a relaxation in part mediated by bradykinin, although in some vascular territories, it might not play an important role in basal tone. 35 Thus, the present work shows that in rat resistance mesenteric arteries in situ, flow-induced dilation involves locally produced angiotensin II via endothelial AT 2 receptor activation. Flow-induced AT 2 -dependent activation resulted in NO synthesis by the endothelium. Figure 11 . Immunostaining of the AT 2 receptor in sections of mesenteric resistance arteries isolated from rats. In control experiments, the anti-AT 2 receptor was omitted and no staining could be observed (not shown). View shown is representative of 8 to 10 experiments.
